Two Pfizer vaccines are not a serious study. The immune response is weak to protect against SVT mutations

A study by the University of London in London examined the immune response of healthcare professionals in Britain after the first two Pfizer / BioNTech vaccinations. Researchers found that people who contracted the disease without symptoms or with a moderate course had a single mRNA vaccine and strong protection against coronavirus mutations in Britain and South Africa. Those who did not report the disease showed a stronger immune response, posing a potential risk of developing infection.

Our findings show that people who were vaccinated in the first two and who did not become infected with SARS-CoV-2 were not fully protected from the alleged births and mutations. Rosemary Poitunov, professor of immunology at Krlovsk University in London, said the study highlights the importance of second-line vaccines to protect the population.

The study tested blood samples for the presence and level of immunity against the original SARS-CoV-2 strain and the mutations that first appeared in Britain (B 1.1.7) and South Africa (B 1,351). The researchers found that production of T cells, B cells, and antibodies is associated with disease delay. He studied only two mutations, but assumed their findings would be valid for the Brazilian and Indian mutations.